Rosty Raykov sold $69k of FENC
CHIEF EXECUTIVE OFFICER at FENNEC PHARMACEUTICALS INC.. 10,946 shares at an average of $6.31, traded Apr 1, 2026, filed Apr 2, 2026.
Score components
- +15RoleDirector
- +8Trade size$69k at market
- 0Share of holdings soldSold 8.8% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +1.9%, 3m +66.7%, 6m +60.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001468316-26-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | AGrant or award Common shares10b5-1 | +5,208 | $0.00 | $0 | 109,204 | Apr 2, 2026 |
| Apr 1, 2026 | MOption exercise Common shares10b5-1 | +15,598 | $2.45 | $38k | 124,802 | Apr 2, 2026 |
| Apr 1, 2026 | SOpen-market sale Common shares10b5-1 | -10,946 | $6.31 | $69k | 113,856 | Apr 2, 2026 |
| Apr 1, 2026 | MOption exercise Stock Optionsderivative10b5-1 | -15,598 | $2.45 | $38k | 1,587,390 | Apr 2, 2026 |
Related signals
Other insiders at FENNEC PHARMACEUTICALS INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | FENNEC PHARMACEUTICALS INC. | Marco Maria Brughera director | $160k 15,545 shares | -100% | |
| 13Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov CHIEF EXECUTIVE OFFICER | $121k 10,000 shares | -7% | |
| 61Notable | FENNEC PHARMACEUTICALS INC. | Pierre Sargis Sayad Chief Medical Officer | $146k 12,000 shares | -56% | |
| 35Weak | FENNEC PHARMACEUTICALS INC. | Robert Andrade CHIEF FINANCIAL OFFICER | $884k 75,000 shares | -26% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov CHIEF EXECUTIVE OFFICER | $96k 10,000 shares | -7% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov CHIEF EXECUTIVE OFFICER | $100k 9,599 shares | -6% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov CHIEF EXECUTIVE OFFICER | $94k 9,747 shares | -7% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Chris A Rallis director | $59k 8,346 shares | -12% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov CHIEF EXECUTIVE OFFICER | $70k 10,781 shares | -8% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov CHIEF EXECUTIVE OFFICER | $84k 10,079 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.